Form 8-K - Current report:
SEC Accession No. 0001213900-25-026270
Filing Date
2025-03-31
Accepted
2025-03-31 16:15:17
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0236324-8k_unicycive.htm   iXBRL 8-K 26620
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MARCH 31, 2025 ea023632401ex99-1_unicycive.htm EX-99.1 52681
3 GRAPHIC ex99-1_001.jpg GRAPHIC 16817
  Complete submission text file 0001213900-25-026270.txt   287003

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE uncy-20250331.xsd EX-101.SCH 3017
5 XBRL LABEL FILE uncy-20250331_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE uncy-20250331_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0236324-8k_unicycive_htm.xml XML 3775
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 25793425
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)